Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
1. Exact Sciences reported a Q2 2025 EPS loss of 1 cent, beating estimates. 2. Revenues rose to $811 million, exceeding analyst expectations of $774 million. 3. The company raised its 2025 sales guidance to $3.13-3.17 billion. 4. EXAS acquired exclusive rights to Freenome's CRC blood screening tests. 5. Analysts predict improving numbers despite a 12.3% drop in EXAS stock.